TOP > 外国特許検索 > CURCUMIN-BORON COMPLEX AND PHARMACEUTICAL CONTAINING SAME

CURCUMIN-BORON COMPLEX AND PHARMACEUTICAL CONTAINING SAME

外国特許コード F170009274
整理番号 E112P09WO
掲載日 2017年10月31日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP011232
国際公開番号 WO 2017164172
国際出願日 平成29年3月21日(2017.3.21)
国際公開日 平成29年9月28日(2017.9.28)
優先権データ
  • 特願2016-056615 (2016.3.22) JP
発明の名称 (英語) CURCUMIN-BORON COMPLEX AND PHARMACEUTICAL CONTAINING SAME
発明の概要(英語) Provided are a compound that is bioapplicable and amyloid-selective, and is useful as an amyloid oxidation catalyst applicable not only to aβ peptides but to other amyloids as well, and a preventive/therapeutic agent for amyloid-related diseases using the same. A curcumin-boron complex represented by general formula (1) (wherein: X1 and X2 are identical or different, and represent a halogenoalkyl group or an halogen atom; X3 represents a bromine atom, an iodine atom, or a selenium atom; R1 and R2 are identical or different, and represent a hydrogen atom or an optionally substituted alkyl group; R3 and R4 are identical or different, and represent a hydrogen atom, a halogen atom, an alkoxy group, or an optionally substituted alkyl group, or R1 and R3 or R2 and R4 together may form an optionally substituted alkylene group or alkenylene group; R5 and R6 are identical or different, and represent a hydrogen atom or an optionally substituted alkyl group; R7 and R8 are identical or different, and represent a hydrogen atom, a halogen atom, an alkoxy group, or an optionally substituted alkyl group, or R5 and R7 or R6 and R8 together may form an optionally substituted alkylene group or alkenylene group; and m and n represent integers from 1 to 3), or a salt thereof.
従来技術、競合技術の概要(英語) BACKGROUND ART
Usually, by folding of the protein, to form a specific native are responsible for vital functions, on the other hand misfolding can be aggregated into β-sheet structure rich fibers sometimes (amyloid-). In the course of the production of the amyloid aggregates (oligomers, proto-fibrillar, fibers) known to cause various functions and disorders (such conditions include 'amyloid' collectively referred to as a), of one or more 20 of the amyloid protein have been identified as the causative agent. Amyloid such as, for example, β amyloid Alzheimer's disease, tau protein, Parkinson's disease α-synuclein, amylin diabetes, systemic - cis transthyretin, such as Huntington's disease Huntingtin is known.
These pathogenic amyloid development of therapeutics targeting strategy include, for example Alzheimer's disease amyloid amyloid β with respect to (abbreviated as A β), precursor protein from an inhibitor of an enzyme that A β, accelerator A β-degrading enzyme, immunotherapy, or the like of the aggregation-inhibiting A β is known. On the other hand, with respect to A β, oxygenation of the body A β peptide Met (A β peptide Met residues and a sulfur atom oxygenized (O) oxygen ligand) a small amount remains within the living body, and the oxygenation Met A β body is unlikely to be agglomerates as compared to the peptide have been reported (non-patent document 1-3). From such a viewpoint, the present inventors, represented by the formula flavin binding site A β using photocatalyst A β peptide A β peptide oxygenized and oxygenation was obtained, the oxygenized body A β A β peptide is reported to suppress the flocculation of (non-patent document 4).
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • JAPAN SCIENCE AND TECHNOLOGY AGENCY
  • 発明者(英語)
  • KANAI, Motomu
  • SOMA, Yohei
  • NI, Jizhi
  • TANIGUCHI, Atsuhiko
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
参考情報 (研究プロジェクト等) ERATO KANAI Life Science Catalysis AREA
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close